RxMP Therapeutics is developing novel hemostatic agents that are designed to arrest or prevent excessive bleeding, thus reducing the need for transfused blood. Based on inexpensively manufactured red blood cell microparticles (RMPs), the company’s agents are administered systemically to accelerate clotting processes. RMPs are intended for use alone or with locally applied hemostatic agents. Potential applications include surgery, trauma, and primary or acquired bleeding disorders, including those resulting from chemotherapy or the use of non-reversible anticoagulants.

RxMP Therapeutics is privately held, founded in 2013 and headquartered in Miami, Florida. The company’s technology was co-invented by Yeon Ahn, MD and Wenche Jy, Ph.D. from the University of Miami, who are leading experts in bleeding disorders and platelet function. RxMP Therapeutics holds exclusive worldwide rights to this technology through a license from the University of Miami. RxMP Therapeutics’ technology and products are covered by a strong intellectual property position, with patents issued in the United States, European Union and Japan, as well as additional applications in review

Since its founding, RxMP Therapeutics has raised initial funding from the Wallace H. Coulter Foundation and The Florida Institute for the Commercialization of Public Research. In addition to financial support, the Wallace H. Coulter Foundation provides the company with business advisory support.